STAT Plus: As demand for Covid shots wanes, Moderna seeks its next success
More than two years after the development of its vaccine, Moderna faces a changing business and regulatory environment.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
STAT Plus: Two type 1 diabetes patients now freed from insulin shots with cell therapy, Vertex reports
STAT Plus: Shareholders elect director’s romantic partner to Biogen’s board
STAT Plus: In setback, Pfizer abandons one weight loss pill and bets on another
STAT Plus: Illumina to lay off 10% of research and development team in bid to cut costs by $100 million
All Coverage
advertisement
